Literature DB >> 27618869

Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.

Katsuaki Ieguchi1, Yoshiro Maru1.   

Abstract

Entities:  

Year:  2016        PMID： 27618869      PMCID： PMC4999676          DOI： 10.21037/jtd.2016.07.56

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

Review 1.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

2.  Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis.

Authors:  Mohamed M Thabet; Tom W J Huizinga
Journal:  Curr Opin Investig Drugs       Date:  2006-11

3.  ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.

Authors:  Camilla Fröhlich; Camilla Nehammer; Reidar Albrechtsen; Pauliina Kronqvist; Marie Kveiborg; Atsuko Sehara-Fujisawa; Arthur M Mercurio; Ulla M Wewer
Journal:  Mol Cancer Res       Date:  2011-08-29       Impact factor: 5.852

4.  Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion.

Authors:  K Iba; R Albrechtsen; B J Gilpin; F Loechel; U M Wewer
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

Review 5.  ADAMs in cancer cell proliferation and progression.

Authors:  Satsuki Mochizuki; Yasunori Okada
Journal:  Cancer Sci       Date:  2007-03-09       Impact factor: 6.716

Review 6.  Eph as a target in inflammation.

Authors:  Katsuaki Ieguchi
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2015       Impact factor: 2.895

7.  Crystal structure of the catalytic domain of human ADAM33.

Authors:  Peter Orth; Paul Reichert; Wenyan Wang; Winifred W Prosise; Taisa Yarosh-Tomaine; Gerald Hammond; Richard N Ingram; Li Xiao; Urooj A Mirza; Jun Zou; Corey Strickland; S Shane Taremi; Hung V Le; Vincent Madison
Journal:  J Mol Biol       Date:  2004-01-02       Impact factor: 5.469

8.  An essential role for ectodomain shedding in mammalian development.

Authors:  J J Peschon; J L Slack; P Reddy; K L Stocking; S W Sunnarborg; D C Lee; W E Russell; B J Castner; R S Johnson; J N Fitzner; R W Boyce; N Nelson; C J Kozlosky; M F Wolfson; C T Rauch; D P Cerretti; R J Paxton; C J March; R A Black
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

9.  Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

Authors:  Frances M Richards; Christopher J Tape; Duncan I Jodrell; Gillian Murphy
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

10.  The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor.

Authors:  Azeddine Atfi; Emmanuelle Dumont; Frédéric Colland; Dominique Bonnier; Annie L'helgoualc'h; Céline Prunier; Nathalie Ferrand; Bruno Clément; Ulla M Wewer; Nathalie Théret
Journal:  J Cell Biol       Date:  2007-07-09       Impact factor: 10.539
View more
  5 in total

Review 1.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 2.  The EPH/Ephrin System in Colorectal Cancer.

Authors:  Stavros P Papadakos; Leonidas Petrogiannopoulos; Alexandros Pergaris; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

3.  ADAM17-Mediated Reduction in CD14++CD16+ Monocytes ex vivo and Reduction in Intermediate Monocytes With Immune Paresis in Acute Pancreatitis and Acute Alcoholic Hepatitis.

Authors:  Kathryn Waller; Charlotte James; Anja de Jong; Laura Blackmore; Yun Ma; Andrew Stagg; David Kelsell; Michael O'Dwyer; Robert Hutchins; William Alazawi
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

4.  Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions.

Authors:  Katsuaki Ieguchi; Takeshi Tomita; Toshifumi Takao; Tsutomu Omori; Taishi Mishima; Isao Shimizu; Massimiliano Tognolini; Alessio Lodola; Takuya Tsunoda; Shinichi Kobayashi; Satoshi Wada; Yoshiro Maru
Journal:  Int J Mol Sci       Date:  2021-03-01       Impact factor: 5.923

Review 5.  Inactive rhomboid proteins RHBDF1 and RHBDF2 (iRhoms): a decade of research in murine models.

Authors:  Lisa M Burzenski; Benjamin E Low; Vivek Kohar; Leonard D Shultz; Michael V Wiles; Vishnu Hosur
Journal:  Mamm Genome       Date:  2021-09-03       Impact factor: 2.957
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.